Democratising real-world drug discovery through agentic AI
Review article, 2026

Agentic systems that are based on large language models (LLMs) have emerged as promising tools in the chemistry domain over the past few years. Early examples included work on CoScientist, Chemcrow, and LLM-RDF, which showcased the potential of agentic systems to assist in chemical research, in the orchestration of cheminformatics tools, and in synthetic reaction development. Despite this, the current literature lacks examples of the real-world adoption of such systems in drug discovery. We present such an example by describing our work on an agentic system called ChatInvent, which has been integrated into the discovery pipeline at AstraZeneca to aid in molecular design and synthesis planning. We discuss how the system evolved from a proof-of-concept single agent into an extensible, robust, and scalable multi-agent architecture with a graphical user interface. We emphasize the lessons learnt and the challenges that persist as we continue to work on this project, and share our perspectives on the future of agentic systems in our domain.

LLMs

automation

agents

drug discovery

AI

Author

Jiazhen He

AstraZeneca AB

Helen Lai

AstraZeneca AB

Lakshidaa Saigiridharan

AstraZeneca AB

Gian Marco Ghiandoni

AstraZeneca AB

Kinga Jenei

AstraZeneca AB

Umur Gokalp

AstraZeneca AB

Ajša Nuković

AstraZeneca AB

Ola Engkvist

Chalmers, Computer Science and Engineering (Chalmers), Data Science and AI

AstraZeneca AB

Jon Paul Janet

AstraZeneca AB

Samuel Genheden

AstraZeneca AB

Drug Discovery Today

1359-6446 (ISSN) 18785832 (eISSN)

Vol. 31 2 104605

Subject Categories (SSIF 2025)

Computer Vision and learning System

Artificial Intelligence

DOI

10.1016/j.drudis.2026.104605

PubMed

41548711

More information

Latest update

2/11/2026